SecBot SecBot
Institutional Cluster

PVLA

PALVELLA THERAPEUTICS, INC.
BULLISH
Impact 6/10
Horizonweeks Processed3mo ago
Institutional cluster: 13 buyers, 1 sellers (bullish)
Actionable Insight ▲ Bullish

The strong institutional accumulation, especially by major holders like Jennison Associates, signals conviction in the NDA submission catalyst. Monitor for completion of the rolling NDA submission in H2 2026 and any regulatory updates. The $250.6M cash runway through 2027 reduces near-term dilution risk. The lack of insider buying (confluence score 22/100, divergent) tempers the signal slightly but does not negate the institutional vote of confidence.

DirectionBullish
Confidencehigh
Horizonweeks

How the stock moved after the report

BULLISH VIEWSTOCK BELOW ENTRY AT T+60
Entry
$152.22
T+0 close · Aug 9, 2026 · via day close
Latest settled
−0.28%
T+60 · $151.80
Vs SPY
+1.62%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Aug 10 $152.22entry
  2. T+1 · 3mo ago +1.37%α +1.69% · $154.30
  3. T+5 · 3mo ago +0.85%α +0.90% · $153.52
  4. T+20 · 2mo ago +3.14%α +4.05% · $157.00
  5. T+60 · 14d ago −0.28%α +1.62% · $151.80

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

13 institutional buyers accumulated $83.1M in PVLA during Q2 2026, led by Jennison Associates adding $66.9M (50% increase), while only one seller trimmed $1.04M. This strong accumulation follows the company's Q2 earnings miss (mechanical EPS miss for pre-revenue biotech) and aligns with the ongoing rolling NDA submission for QTORIN rapamycin in microcystic lymphatic malformations, on track for completion in H2 2026.

Key Financial Metrics

Direction
accumulating
Buy Value
$179.4M
Sell Value
$2.6M
Net Flow
$82.1M

Institutional Positions

Net institutional flow: $82.1M

▲ Buyers (13)

InstitutionActionChangePosition ValueValue Δ
Jennison AssociatesADD+50%$146.8M$66.9M
Aberdeen GroupADD+48.3%$18.4M$8.3M
Bank Of New York MellonADD+69.5%$4.7M$2.4M
CitigroupDOUBLED+518.7%$2.4M$2.1M
Russell Investments GroupADD+65.2%$3.4M$1.7M

▼ Sellers (1)

InstitutionActionChangePrev ValueValue Δ
New York State Common Retirement FundTRIM-50.7%$2.6M-$1.0M

Key Facts

  • 13 institutional buyers vs 1 seller in Q2 2026
  • Net institutional inflow of $83.1M, with total buyer holdings of $179.4M
  • Jennison Associates added $66.9M (50% increase to $146.8M)
  • Aberdeen Group added $8.3M (48.3% increase to $18.4M)
  • Only seller: New York State Common Retirement Fund trimmed $1.04M (50.7% reduction)
  • Q2 2026 EPS miss of -$1.52 vs consensus -$1.15 (32% miss) was a mechanical artifact of increased R&D and dilution, not business deterioration
  • Cash position of $250.6M funds operations and launch preparations through 2027
  • NDA submission for QTORIN rapamycin on track for H2 2026, potential U.S. launch H1 2027

Financial Impact

Net institutional accumulation of $83.1M in Q2 2026, with 13 buyers adding $83.1M and 1 seller reducing by $1.04M

institutional ownershipfloatstock price

Risk Factors

  • Clinical and regulatory risk: NDA submission may face delays or rejection
  • Pre-revenue stage: no approved products, reliance on pipeline success
  • Potential dilution from future equity raises despite current cash position

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
95% bullish (22 analysts)

Investment Themes

Documents Analyzed

This report is based on 1 institutional 13F filing from SEC EDGAR.

DocumentAccession Number
INST-CLUSTER Data (Synthetic)inst-cluster-PVLA-2026-Q2

Track record

36 reports on PVLA

Performance horizon

3 of 6 bullish or bearish reports moved the stock their way by T+20. Best: +35.07% at T+60 after the May 15, 2026 report. 7 of 9 went positive at some point.

Filters
  1. Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $145.21 settles Dec 16
  2. Nov 10, 20266d ago 144 Neutral 5/10 Entry $163.94 settles Dec 10
  3. Nov 5, 202611d ago 8-K Bullish 7/10 Entry $156.85 settles Dec 4
  4. Nov 5, 202611d ago Press Release Neutral 6/10 No price data
  5. Nov 3, 202613d ago Institutional Cluster Neutral 2/10 Entry $152.93 settles Dec 2
  6. Oct 28, 202619d ago SC 13G/A Neutral 3/10 Entry $147.47 settles Nov 25
  7. Oct 28, 202619d ago 8-K Bullish 6/10 Entry $147.47 settles Nov 25
  8. Oct 28, 202619d ago Press Release Bullish 7/10 Entry $147.47 settles Nov 25
  9. Oct 23, 202624d ago Insider Cluster Neutral 2/10 Entry $126.23 settles Nov 23
  10. Oct 15, 20264w ago Press Release Neutral 4/10 Entry $127.34 to $153.18 ▲ +20.29% +22.19% vs SPY
Showing 10 of 36

US Market Status

Market Closed · Opens in 6h 13m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Aug 9, 2026